Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $19.00.

A number of analysts have recently issued reports on ARTV shares. HC Wainwright lifted their target price on Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Jefferies Financial Group upgraded Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock opened at $5.65 on Monday. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $7.36. The company has a market capitalization of $138.58 million, a price-to-earnings ratio of -2.12 and a beta of 2.12. The firm’s fifty day moving average price is $4.43 and its 200 day moving average price is $3.76.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ARTV. Y Intercept Hong Kong Ltd bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth about $48,000. Marshall Wace LLP bought a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $79,000. Qube Research & Technologies Ltd acquired a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $58,000. Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at approximately $67,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $53,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.